JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients

Trial Title: JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients

NCT ID: NCT05800535

Condition: Cancer
Sarcopenia

Conditions: Official terms:
Sarcopenia
Chemotherapy-Related Cognitive Impairment

Conditions: Keywords:
Post cancer
Chemobrain
Sarcopenia
Medical evaluation

Study type: Observational

Overall status: Active, not recruiting

Study design:

Time perspective: Retrospective

Intervention:

Intervention type: Drug
Intervention name: Study of the adverse effects of long-term oncological treatments
Description: Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
Arm group label: JUMP Cohort

Intervention type: Behavioral
Intervention name: Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients
Description: Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
Arm group label: JUMP Cohort

Summary: Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital). JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers. This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day. This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received. Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.

Criteria for eligibility:

Study pop:
patients who have been treated for cancer and who have completed the post-cancer assessment day

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - Age : 18 to 74 years - localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy - patient who benefited from the post-cancer assessment day- Exclusion Criteria: - Under 18years - Over 74 years - Patient who did not received any chemical treatment - Patient who do not wish to participate

Gender: All

Minimum age: 18 Years

Maximum age: 74 Years

Healthy volunteers: No

Locations:

Facility:
Name: Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud

Address:
City: Pierre-Bénite
Zip: 69310
Country: France

Start date: March 1, 2023

Completion date: December 31, 2028

Lead sponsor:
Agency: Hospices Civils de Lyon
Agency class: Other

Source: Hospices Civils de Lyon

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05800535